Jeffrey P. Mornhinweg

Array ( [id] => 15708775 [patent_doc_number] => 20200101153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => MVA-BN AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMEN [patent_app_type] => utility [patent_app_number] => 16/500567 [patent_app_country] => US [patent_app_date] => 2018-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22224 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16500567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17266422 [patent_doc_number] => 11191826 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Modified viruses [patent_app_type] => utility [patent_app_number] => 16/612842 [patent_app_country] => US [patent_app_date] => 2018-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 21 [patent_no_of_words] => 15825 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17267515 [patent_doc_number] => 11192926 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use [patent_app_type] => utility [patent_app_number] => 16/500331 [patent_app_country] => US [patent_app_date] => 2018-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 17 [patent_no_of_words] => 15773 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 269 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16500331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15454971 [patent_doc_number] => 20200040310 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => ADDITION OF NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND CLEARANCE OF HOST CELL NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 16/498013 [patent_app_country] => US [patent_app_date] => 2018-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9251 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646813 [patent_doc_number] => 20200085936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => VLP-BASED BIVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME [patent_app_type] => utility [patent_app_number] => 16/494841 [patent_app_country] => US [patent_app_date] => 2018-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6607 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16494841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16353364 [patent_doc_number] => 10793866 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-06 [patent_title] => Edible vaccines expressed in yeast for preventing and treating infectious diseases, including hepatitis B, in humans [patent_app_type] => utility [patent_app_number] => 15/937622 [patent_app_country] => US [patent_app_date] => 2018-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1722 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15937622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13106879 [patent_doc_number] => 10072072 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-11 [patent_title] => Antibody neutralizing human respiratory syncytial virus [patent_app_type] => utility [patent_app_number] => 15/928566 [patent_app_country] => US [patent_app_date] => 2018-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 16 [patent_no_of_words] => 32044 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15928566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14454255 [patent_doc_number] => 10323079 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-18 [patent_title] => Antibody neutralizing human respiratory syncytial virus [patent_app_type] => utility [patent_app_number] => 15/928503 [patent_app_country] => US [patent_app_date] => 2018-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 16 [patent_no_of_words] => 32064 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15928503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13328541 [patent_doc_number] => 20180215808 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS [patent_app_type] => utility [patent_app_number] => 15/928438 [patent_app_country] => US [patent_app_date] => 2018-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31895 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15928438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14388441 [patent_doc_number] => 10307478 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-04 [patent_title] => Biochemically stabilized HIV-1 Env trimer vaccine [patent_app_type] => utility [patent_app_number] => 15/919834 [patent_app_country] => US [patent_app_date] => 2018-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 23 [patent_no_of_words] => 13706 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15919834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13372425 [patent_doc_number] => 20180237753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCING VIRUS REPLICATION [patent_app_type] => utility [patent_app_number] => 15/919554 [patent_app_country] => US [patent_app_date] => 2018-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15919554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14088081 [patent_doc_number] => 10239934 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-26 [patent_title] => Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity [patent_app_type] => utility [patent_app_number] => 15/918343 [patent_app_country] => US [patent_app_date] => 2018-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 65 [patent_figures_cnt] => 73 [patent_no_of_words] => 49788 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15918343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16310935 [patent_doc_number] => 20200289673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => TREATMENT OF GLYCOGEN STORAGE DISEASE III [patent_app_type] => utility [patent_app_number] => 16/491623 [patent_app_country] => US [patent_app_date] => 2018-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16361 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16491623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14393377 [patent_doc_number] => 10309965 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-04 [patent_title] => Method and kit for determining the probability that a patient will develop a severe case of dengue [patent_app_type] => utility [patent_app_number] => 15/912730 [patent_app_country] => US [patent_app_date] => 2018-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 7110 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15912730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13958355 [patent_doc_number] => 20190055521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => Methods Of Propagating Rhinovirus C In Previously Unsusceptible Cell Lines [patent_app_type] => utility [patent_app_number] => 15/913058 [patent_app_country] => US [patent_app_date] => 2018-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15913058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12912607 [patent_doc_number] => 20180196045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => METHOD AND KIT FOR DETERMINING THE PROBABILITY THAT A PATIENT WILL DEVELOP A SEVERE CASE OF DENGUE [patent_app_type] => utility [patent_app_number] => 15/912695 [patent_app_country] => US [patent_app_date] => 2018-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7118 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15912695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17815648 [patent_doc_number] => 11421247 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Borna viral vector and use thereof [patent_app_type] => utility [patent_app_number] => 16/493232 [patent_app_country] => US [patent_app_date] => 2018-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 12 [patent_no_of_words] => 18239 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16493232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17569943 [patent_doc_number] => 11318197 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-03 [patent_title] => Compositions and methods for inducing HIV-1 antibodies [patent_app_type] => utility [patent_app_number] => 16/489245 [patent_app_country] => US [patent_app_date] => 2018-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 207 [patent_figures_cnt] => 176 [patent_no_of_words] => 39183 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16489245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13763917 [patent_doc_number] => 10174293 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2019-01-08 [patent_title] => Recombinant PB1 bacteriophages and uses thereof [patent_app_type] => utility [patent_app_number] => 15/908140 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 41 [patent_no_of_words] => 12743 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15908140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13763919 [patent_doc_number] => 10174294 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2019-01-08 [patent_title] => Recombinant K2 bacteriophages and uses thereof [patent_app_type] => utility [patent_app_number] => 15/908162 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 90 [patent_figures_cnt] => 97 [patent_no_of_words] => 15900 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15908162 [rel_patent_id] =>[rel_patent_doc_number] =>)